AI digital-biomarker projects in TD, schizophrenia and MSA
Diagnostics and clinical decision support Deployment
Disclosed: Verified:
Teva's chief medical officer says Teva is using AI for digital-biomarker projects that include a facial-recognition tool for tardive dyskinesia diagnosis (extracting ~500 facial landmarks), an automated speech-based tool relating voice parameters to the PANSS scale, and wearable movement sensors correlated with clinical outcomes in multiple system atrophy.
Source
Company Archive pending